Relay Therapeutics (RLAY) closed at $18.03 on November 4, 2026, up 3.4% from the previous close, on volume of 3,386,457 shares (30-day average 2,540,915).
Data as of November 4, 2026.
Relay Therapeutics (RLAY) Gets a Buy from Barclays
TipRanks (Thu, 5-Nov 3:41 AM ET)
Relay Therapeutics GAAP EPS of -$0.37 beats by $0.03
Seeking Alpha News (Wed, 4-Nov 5:26 PM ET)
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Globe Newswire (Wed, 28-Oct 4:12 PM ET)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Globe Newswire (Tue, 1-Sep 4:46 PM ET)
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Relay Therapeutics’ $275 Million Offering: What the Major Capital Raise Signals for RLAY
Market Chameleon (Thu, 21-May 6:32 AM ET)
Relay Therapeutics' $275 Million Offering Bolsters Pipeline Ambitions—Key Details for Investors
Market Chameleon (Thu, 21-May 4:15 AM ET)
Market Chameleon (Mon, 16-Mar 3:53 AM ET)
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Relay Therapeutics trades on the NASDAQ stock market under the symbol RLAY.
As of November 5, 2026, RLAY stock price declined to $17.42 with 290,963 million shares trading.
RLAY has a beta of 1.91, meaning it tends to be more sensitive to market movements. RLAY has a correlation of 0.14 to the broad based SPY ETF.
RLAY has a market cap of $3.82 billion. This is considered a Mid Cap stock.
Last quarter Relay Therapeutics reported $0 in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.03.
In the last 3 years, RLAY traded as high as $21.27 and as low as $1.78.
The top ETF exchange traded funds that RLAY belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
RLAY has outperformed the market in the last year with a return of +153.9%, while the SPY ETF gained +12.6%. However, in the most recent history, RLAY shares have underperformed the stock market with its stock returning -10.8% in the last 3 month period and -5.4% for the last 2 week period, while SPY has returned -2.2% and -2.6%, respectively.
RLAY support price is $17.32 and resistance is $18.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLAY shares will trade within this expected range on the day.
